{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:48:00Z","timestamp":1790743680828,"version":"4.1.0"},"reference-count":84,"publisher":"Institute of Biochemistry","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BIOMED KHIM"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>Asparaginase is one of the most important chemotherapeutic agents against acute lymphoblastic leukemia, the most common form of blood cancer. To date, both asparaginases from E. coli and Dickeya dadantii (formerly known as Erwinia chrysanthemi), used in hematology, induce chemoresistance in cancer cells and side effects in the form of hypersensitivity of immune reactions. Leukemic cells may be resistant to asparaginase due to the increased activity of asparagine synthetase and other mechanisms associated with resistance to asparaginase. Therefore, the search for new sources of L-asparaginases with improved pharmacological properties remains a promising and prospective study. This article discusses the mechanisms of development of resistance and drug resistance to L-asparaginase, as well as possible ways to overcome them.<\/jats:p>","DOI":"10.18097\/pbmc20226802104","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T10:31:19Z","timestamp":1651228279000},"page":"104-116","source":"Crossref","is-referenced-by-count":8,"title":["Mechanisms of development of side effects and drug resistance to asparaginase and ways to overcome them"],"prefix":"10.18097","volume":"68","author":[{"given":"S.S.","family":"Alexandrova","sequence":"first","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.A.","family":"Gladilina","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Pokrovskaya","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.N.","family":"Sokolov","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.D.","family":"Zhdanov","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7443","published-online":{"date-parts":[[2022]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Pokrovsky V.S., Chepikova O.E., Davydov D.Z., Zamyatnin A.A. Jr., Lukashev A.N., Lukasheva E.V. (2019) Amino acid degrading enzymes and their application in cancer therapy. Curr. Med. Chem., 26, 446-464.","DOI":"10.2174\/0929867324666171006132729"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Beckett A., Gervais D. (2019) What makes a good new therapeutic L-asparaginase? World J. Microbiol. Biotechnol., 35, 152.","DOI":"10.1007\/s11274-019-2731-9"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Dinndorf P.A., Gootenberg J., Cohen M.H., Keegan P., Pazdur R. (2007) FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist, 12, 991-998.","DOI":"10.1634\/theoncologist.12-8-991"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Jaccard A., Petit B., Girault S., Suarez F., Gressin R., Zini J.-M., Coiteux V., Larroche C., Devidas A., Thi\u00e9blemont C., Gaulard P., Marin B., Gachard N., Bordessoule D., Hermine O. (2009) L-asparaginase-based treatment of 15 western patients with extranodal NK\/T-cell lymphoma and leukemia and a review of the literature. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 20, 110-116.","DOI":"10.1093\/annonc\/mdn542"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"V\u00f6ller S., Pichlmeier U., Zens A., Hempel G. (2018) Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia. Cancer Chemother. Pharmacol., 81, 305-314.","DOI":"10.1007\/s00280-017-3492-5"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Chien W.-W., Allas S., Rachinel N., Sahakian P., Julien M., Le Beux C., Lacroix C.-E., Abribat T., Salles G. (2014) Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. Invest. New Drugs., 32, 795-805.","DOI":"10.1007\/s10637-014-0102-9"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Sharma D., Singh K., Singh K., Mishra A. (2018) Insights into the microbial L-asparaginases: from production to practical applications. Curr. Protein Pept. Sci., 20, 452-464.","DOI":"10.2174\/1389203720666181114111035"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Lubkowski J., Vanegas J., Chan W.-K., Lorenzi P.L., Weinstein J.N., Sukharev S., Fushman D., Rempe S., Anishkin A., Wlodawer A. (2020) Mechanism of catalysis by L-asparaginase. Biochemistry, 59, 1927-1945.","DOI":"10.1021\/acs.biochem.0c00116"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Ghasemian A., Al-Marzoqi A.H., Al-Abodi H.R., Alghanimi Y.K., Kadhum S.A., Shokouhi Mostafavi S.K., Fattahi A. (2019) Bacterial L-asparaginases for cancer therapy: current knowledge and future perspectives. J. Cell. Physiol., 234, 19271-19279.","DOI":"10.1002\/jcp.28563"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Batool T., Makky E.A., Jalal M., Yusoff M.M. (2016) A comprehensive review on L-asparaginase and its applications. Appl. Biochem. Biotechnol., 178, 900-923.","DOI":"10.1007\/s12010-015-1917-3"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Michalska K., Jaskolski M. (2006) Structural aspects of L-asparaginases, their friends and relations. Acta Biochim. Pol., 53, 627-640.","DOI":"10.18388\/abp.2006_3291"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Niu J., Meng F., Zhou Y., Zhang C., Lu Z., Lu F., Chen M. (2021) Non-classical secretion of a type I L-asparaginase in Bacillus subtilis. Int. J. Biol. Macromol., 180, 677-683.","DOI":"10.1016\/j.ijbiomac.2021.03.104"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Yao M., Yasutake Y., Morita H., Tanaka I. (2005) Structure of the type I L-asparaginase from the hyperthermophilic archaeon Pyrococcus horikoshii at 2.16 angstroms resolution. Acta Crystallogr. D. Biol. Crystallogr., 61, 294-301.","DOI":"10.1107\/S0907444904032950"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Jiao L., Chi H., Lu Z., Zhang C., Chia S.R., Show P.L., Tao Y., Lu F. (2020) Characterization of a novel type I L-asparaginase from Acinetobacter soli and its ability to inhibit acrylamide formation in potato chips. J. Biosci. Bioeng., 129, 672-678.","DOI":"10.1016\/j.jbiosc.2020.01.007"},{"key":"ref15","unstructured":"Sharafi Z., Barati M., Khoshayand M.R., Adrangi S. (2017) Screening for type II L-asparaginases: lessons from the genus halomonas. Iran. J. Pharm. Res. IJPR., 16, 1565-1573."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Nowak-Gottl U., Wolff J.E.A., Kuhn N., Boos J., Kehrel B., Lilienweiss V., Schwabe D., J\u00fcrgens H. (1994) Enhanced thrombin generation, P-von willebrand factor, P-fibrin D-dimer and P-plasminogen activator inhibitor 1: Predictive for venous thrombosis in asparaginase-treated children. Fibrinolysis, 8, 63-65.","DOI":"10.1016\/0268-9499(94)90248-8"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Leibundgut K., Hirt A., Zwicky C., Wuillemin W.A. (2003) Cerebral sinovenous thrombosis during asparaginase treatment. Case 3. Hamostaseologie, 23, 109-112.","DOI":"10.1055\/s-0037-1619586"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Fonseca M.H.G., Fi\u00faza T.D.S., de Morais S.B., de Souza C.B., Trevizani R. (2021) Circumventing the side effects of L-asparaginase. Biomed. Pharmacother., 139, 111616.","DOI":"10.1016\/j.biopha.2021.111616"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"da Silva Lacerda G.R., Cantalice J.C.L.L., de Souza Lima G.M., de Albuquerque L.E.F., da Silva I.D.G., de Melo M.E.B., Adam M.L., do Nascimento S.C. (2019) Genotoxic activity of L-asparaginase produced by Streptomyces ansochromogenes UFPEDA 3420, World J. Microbiol. Biotechnol., 35, 41.","DOI":"10.1007\/s11274-019-2612-2"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Aghaiypour K., Wlodawer A., Lubkowski J. (2001) Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase, Biochemistry, 40, 5655-5664.","DOI":"10.1021\/bi0029595"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Kessel D. (1971) Asparaginyl-transfer RNA. A substrate for L-asparaginase, BBA Sect. Nucleic Acids Protein Synth., 240, 554-557.","DOI":"10.1016\/0005-2787(71)90712-X"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Bosmann H.B., Kessel D. (1970) Inhibition of glycoprotein synthesis in L5178Y mouse leukaemic cells by L-asparaginase in vitro. Nature, 226, 850-851.","DOI":"10.1038\/226850a0"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Ankel E.G., Zirneski J., Ring B.J., Holcenberg J.S. (1984) Effect of asparaginase on cell membranes of sensitive and resistants mouse lymphoma cells. In Vitro, 20, 376-384.","DOI":"10.1007\/BF02619582"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Zhdanov D.D., Pokrovsky V.S., Pokrovskaya M.V., Alexandrova S.S., Eldarov M.A., Grishin D.V., Basharov M.M., Gladilina Y.A., Podobed O.V., Sokolov N.N. (2017) Rhodospirillum rubrum L-asparaginase targets tumor growth by a dual mechanism involving telomerase inhibition. Biochem. Biophys. Res. Commun., 492, 282-288.","DOI":"10.1016\/j.bbrc.2017.08.078"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Zhdanov D.D., Pokrovsky V.S., Pokrovskaya M.V., Alexandrova S.S., Eldarov M.A., Grishin D.V., Basharov M.M., Gladilina Y.A., Podobed O.V., Sokolov N.N. (2017) Inhibition of telomerase activity and induction of apoptosis by Rhodospirillum rubrum L-asparaginase in cancer Jurkat cell line and normal human CD4+ T lymphocytes. Cancer Med., 6, 2697-2712.","DOI":"10.1002\/cam4.1218"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Plyasova A.A., Pokrovskaya M.V., Lisitsyna O.M., Pokrovsky V.S., Alexandrova S.S., Hilal A., Sokolov N.N., Zhdanov D.D. (2020) Penetration into cancer cells via clathrin-dependent mechanism allows L-asparaginase from Rhodospirillum rubrum to inhibit telomerase. Pharmaceuticals, 13, 286.","DOI":"10.3390\/ph13100286"},{"key":"ref27","unstructured":"Kidd J.G., Sobin L.H. (1966) The incorporation of L-asparagine-14C by lymphoma 6C3HED cells: its inhibition by guinea pig serum. Cancer Res., 26, 208-211."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Kidd J.G. (1953) Regression of transplanted lymphomas induced in vivo by means of normal guinea-pig serum: I. Course of transplanted cancer of various kinds in mice and rats given guinea-pig serum, horse serum or rabbit serum. J. Exp. Med., 98, 565-582.","DOI":"10.1084\/jem.98.6.565"},{"key":"ref29","unstructured":"Broome J.D. (1965) Antilymphoma activity of L-asparaginase in vivo: clearance rates of enzyme preparations from guinea pig serum and yeast in relation to their effect on tumor growth. J. Natl. Cancer Inst., 35, 967-974."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Ponomarenko J., Papangelopoulos N., Zajonc D.M., Peters B., Sette A., Bourne P.E. (2011) IEDB-3D: structural data within the immune epitope database. Nucleic Acids Res., 39, D1164-D1170.","DOI":"10.1093\/nar\/gkq888"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Covini D., Tardito S., Bussolati O., Chiarelli L.R., Pasquetto M.V., Digilio R., Valentini G., Scotti C. (2012) Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat. Anticancer. Drug Discov., 7, 4-13.","DOI":"10.2174\/157489212798358001"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Sokolov N.N., Eldarov M.A., Pokrovskaya M.V., Aleksandrova S.S., Abakumova O.Y., Podobed O.V., Melik-Nubarov N.S., Kudryashova E.V., Grishin D.V., Archakov A.I. (2015) Bacterial recombinant L-asparaginases: properties, structure and anti-proliferative activity. Biomeditsinskaya Khimiya, 61(3), 312-324.]","DOI":"10.18097\/PBMC20156103312"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Cantor J.R., Panayiotou V., Agnello G., Georgiou G., Stone E.M. (2012) Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer. Methods Enzymol., 502, 291-319.","DOI":"10.1016\/B978-0-12-416039-2.00015-X"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Hermanova I., Zaliova M., Trka J., Starkova J. (2012) Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase. Exp. Hematol. 40, 657-665.","DOI":"10.1016\/j.exphem.2012.04.005"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Hawkins D.S., Park J.R., Thomson B.G., Felgenhauer J.L., Holcenberg J.S., Panosyan E.H., Avramis V.I. (2004) Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin. Cancer Res., 10, 5335-5341.","DOI":"10.1158\/1078-0432.CCR-04-0222"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Krishnapura P.R., Belur P.D., Subramanya S. (2016) A critical review on properties and applications of microbial L-asparaginases. Crit. Rev. Microbiol., 42, 720-737.","DOI":"10.3109\/1040841X.2015.1022505"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Yamaguchi M., Kwong Y.-L., Kim W.S., Maeda Y., Hashimoto C., Suh C., Izutsu K., Ishida F., Isobe Y., Sueoka E., Suzumiya J., Kodama T., Kimura H., Hyo R., Nakamura S., Oshimi K., Suzuki R. (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J. Clin. Oncol., 29, 4410-4416.","DOI":"10.1200\/JCO.2011.35.6287"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Wang L., Wang Z., Chen X., Li Y., Wang K., Xia Y., Xia Z. (2013) First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE\/IIE extranodal natural killer\/T-cell lymphoma. Cancer, 119, 348-355.","DOI":"10.1002\/cncr.27752"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Jaccard A., Gachard N., Marin B., Rogez S., Audrain M., Suarez F., Tilly H., Morschhauser F., Thieblemont C., Ysebaert L., Devidas A., Petit B., de Leval L., Gaulard P., Feuillard J., Bordessoule D., Hermine O., GELA and GOELAMS Intergroup (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood, 117, 1834-1839.","DOI":"10.1182\/blood-2010-09-307454"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Li X., Cui Y., Sun Z., Zhang L., Li L., Wang X., Wu J., Fu X., Ma W., Zhang X., Chang Y., Nan F., Li W., Su L., Wang J., Xue H., Zhang M. (2016) DDGP versus SMILE in newly diagnosed advanced natural killer\/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin. Cancer Res., 22, 5223-5228.","DOI":"10.1158\/1078-0432.CCR-16-0153"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Hijiya N., van der Sluis I.M. (2016) Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk. Lymphoma, 57, 748-757.","DOI":"10.3109\/10428194.2015.1101098"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"van den Berg H. (2011) Asparaginase revisited. Leuk. Lymphoma, 52, 168-178.","DOI":"10.3109\/10428194.2010.537796"},{"key":"ref43","unstructured":"Avramis V.I., Avramis E.V., Hunter W., Long M.C. (2009) Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res., 29, 299-302."},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Baryshnikova M.A., Baryshnikov A.Y., Afanasieva D.A. (2015) Molecular mechanisms of multidrug resistance overcoming by liposomal antitumor drugs, Russ. J. Biother., 14, 3-10.]","DOI":"10.17650\/1726-9784-2015-14-1-3-10"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Raji\u0107 V., Debeljak M., Gori\u010dar K., Jazbec J. (2015) Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia. Leuk. Lymphoma, 56, 3103-3108.","DOI":"10.3109\/10428194.2015.1020802"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Cantor J.R., Yoo T.H., Dixit A., Iverson B.L., Forsthuber T.G., Georgiou G. (2011) Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc. Natl. Acad. Sci. USA, 108, 1272-1277.","DOI":"10.1073\/pnas.1014739108"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Moola Z.B., Scawen M.D., Atkinson T., Nicholls D.J. (1994) Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem. J., 302, Pt 3 921-927.","DOI":"10.1042\/bj3020921"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Offman M.N., Krol M., Patel N., Krishnan S., Liu J., Saha V., Bates P.A. (2011) Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood, 117, 1614-1621.","DOI":"10.1182\/blood-2010-07-298422"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Jianhua C., Yujun W., Ruibo J., Min W., Wutong W. (2006) Probing the antigenicity of E. coli L-asparaginase by mutational analysis. Mol. Biotechnol., 33, 57-65.","DOI":"10.1385\/MB:33:1:57"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Werner A., R\u00f6hm K.-H., M\u00fcller H.-J. (2005) Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment., Biol. Chem. 386, 535-540.","DOI":"10.1515\/BC.2005.063"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Mehta R.K., Verma S., Pati R., Sengupta M., Khatua B., Jena R.K., Sethy S., Kar S.K., Mandal C., Roehm K.H., Sonawane A. (2014) Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice. J. Biol. Chem., 289, 3555-3570.","DOI":"10.1074\/jbc.M113.486530"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Zeidan A., Wang E.S., Wetzler M. (2009) Pegasparaginase: where do we stand? Expert Opin. Biol. Ther., 9, 111-119.","DOI":"10.1517\/14712590802586058"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Medawar C.V., Mosegui G.B.G., de M. Vianna C.M., da Costa T.M.A. (2019) PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review. Hematol. Transfus. Cell Ther., 42, 54-61.","DOI":"10.1016\/j.htct.01.013"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Pokrovsky V.S., Kazanov M.D., Dyakov I.N., Pokrovskaya M.V., Aleksandrova S.S. (2016) Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases. BMC Cancer, 16, 89.","DOI":"10.1186\/s12885-016-2125-4"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Pokrovskaya M.V., Aleksandrova S.S., Pokrovsky V.S., Veselovsky A.V., Grishin D.V., Abakumova O.Y., Podobed O.V., Mishin A.A., Zhdanov D.D., Sokolov N.N. (2015) Identification of functional regions in the Rhodospirillum rubrum L-asparaginase by site-directed mutagenesis. Mol. Biotechnol., 57, 251-264.","DOI":"10.1007\/s12033-014-9819-0"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Pokrovskaya M.V., Pokrovskiy V.S., Aleksandrova S.S., Anisimova N.Y., Andrianov R.M., Treschalina E.M., Ponomarev G.V., Sokolov N.N. (2012) Recombinant intracellular Rhodospirillum rubrum L-asparaginase with low L-glutaminase activity and antiproliferative effect. Biomeditsinskaya Khimiya, 59(2), 192-208.]","DOI":"10.18097\/pbmc20135902192"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Pokrovskaya M.V., Zhdanov D.D., Eldarov M.A., Aleksandrova S.S., Veselovsky A.V., Pokrovskiy V.S., Grishin D.V., Gladilina J.A., Sokolov N.N. (2017) Suppression of telomerase activity in leukemic cells by mutant forms of Rhodospirillum rubrum L-asparaginase. Biomeditsinskaya Khimiya, 63(1), 62-74.]","DOI":"10.18097\/PBMC20176301062"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Malakhova M.A., Pokrovskaya M.V., Alexandrova S.S., Sokolov N.N., Kudryashova E.V. (2018) Regulation of catalytic activity of recombinant L-asparaginase from Rhodospirillum rubrum by conjugation with a PEG-chitosan copolymer. Moscow Univ. Chem. Bull., 73, 185-191.]","DOI":"10.3103\/S0027131418040065"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Karamitros C.S., Konrad M. (2014) Human 60-kDa lysophospholipase contains an N-terminal L-asparaginase domain that is allosterically regulated by L-asparagine. J. Biol. Chem., 289, 12962-12975.","DOI":"10.1074\/jbc.M113.545038"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Rigouin C., Nguyen H.A., Schalk A.M., Lavie A. (2017) Discovery of human-like L-asparaginases with potential clinical use by directed evolution. Sci. Rep., 7, 10224.","DOI":"10.1038\/s41598-017-10758-4"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Haskell C.M., Canellos G.P. (1969) L-asparaginase resistance in human leukemia \u2013 asparagine synthetase. Biochem. Pharmacol., 18, 2578-2580.","DOI":"10.1016\/0006-2952(69)90375-x"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Chiu M., Taurino G., Bianchi M.G., Kilberg M.S., Bussolati O. (2019) Asparagine synthetase in cancer: beyond acute lymphoblastic leukemia. Front. Oncol., 9, 1480.","DOI":"10.3389\/fonc.2019.01480"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Lomelino C.L., Andring J.T., McKenna R., Kilberg M.S. (2017) Asparagine synthetase: Function, structure, and role in disease. J. Biol. Chem., 292, 19952-19958.","DOI":"10.1074\/jbc.R117.819060"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Liu W.-J., Wang H., Peng X.-W., Wang W., Liu N.-W., Wang Y., Lu Y. (2018) Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer\/T-cell lymphoma in vivo and in vitro. Onco. Targets. Ther., 11, 6605-6615.","DOI":"10.2147\/OTT.S155930"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Aslanian A.M., Fletcher B.S., Kilberg M.S. (2001) Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem. J., 357, 321-328.","DOI":"10.1042\/0264-6021:3570321"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Mei L., Ontiveros E.P., Griffiths E.A., Thompson J.E., Wang E.S., Wetzler M. (2015) Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev., 29, 243-349.","DOI":"10.1016\/j.blre.2015.01.001"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Aslanian A.M., Kilberg M.S. (2001) Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem. J., 358, 59-67.","DOI":"10.1042\/0264-6021:3580059"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Hinze L., Pfirrmann M., Karim S., Degar J., McGuckin C., Vinjamur D., Sacher J., Stevenson K.E., Neuberg D.S., Orellana E., Stanulla M., Gregory R.I., Bauer D.E., Wagner F.F., Stegmaier K., Gutierrez A. (2019) Synthetic lethality of wnt pathway activation and asparaginase in drug-resistant acute leukemias. Cancer Cell, 35, 664-676.e7.","DOI":"10.1016\/j.ccell.2019.03.004"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Richards N.G.J., Kilberg M.S. (2006) Asparagine synthetase chemotherapy. Annu. Rev. Biochem., 75, 629-654.","DOI":"10.1146\/annurev.biochem.75.103004.142520"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Chan W.-K., Horvath T.D., Tan L., Link T., Harutyunyan K.G., Pontikos M.A., Anishkin A., Du D., Martin L.A., Yin E., Rempe S.B., Sukharev S., Konopleva M., Weinstein J.N., Lorenzi P.L. (2019) Glutaminase activity of L-asparaginase contributes to durable preclinical activity against acute lymphoblastic leukemia. Mol. Cancer Ther., 18, 1587-1592.","DOI":"10.1158\/1535-7163.MCT-18-1329"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Nunes J.C.F., Crist\u00f3v\u00e3o R.O., Freire M.G., Santos-Ebinuma V.C., Faria J.L., Silva C.G., Tavares A.P.M. (2020) Recent strategies and applications for L-asparaginase confinement. Molecules, 25, 5827.","DOI":"10.3390\/molecules25245827"},{"key":"ref72","unstructured":"Ohnuma T., Holland J.F., Freeman A., Sinks L.F. (1970) Biochemical and pharmacological studies with asparaginase in man. Cancer Res., 30, 2297-22305."},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Akbayram S., Do\u011fan M., Akg\u00fcn C., Caksen H., Oner A.F. (2010) A desensitization protocol in children with L-asparaginase hypersensitivity. J. Pediatr. Hematol. Oncol., 32, e187-e191.","DOI":"10.1097\/MPH.0b013e3181e003c7"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Pokrovskaya M.V., Pokrovsky V.S., Aleksandrova S.S., Sokolov N.N., Zhdanov D.D. (2022) Molecular analysis of L-asparaginases for clarification of the mechanism of action and optimization of pharmacological functions. Pharmaceutics, 14, 599.","DOI":"10.3390\/pharmaceutics14030599"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Li H., Yang Y., Hong W., Huang M., Wu M., Zhao X. (2020) Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct. Target. Ther., 5, 1.","DOI":"10.1038\/s41392-019-0089-y"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Anishchenko I., Pellock S.J., Chidyausiku T.M., Ramelot T.A., Ovchinnikov S., Hao J., Bafna K., Norn C., Kang A., Bera A.K., di Maio F., Carter L., Chow C.M., Montelione G.T., Baker D. (2021) De novo protein design by deep network hallucination. Nature, 600, 547-552.","DOI":"10.1038\/s41586-021-04184-w"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Evans R., Neill M.O., Pritzel A., Antropova N., Senior A., Green T., \u017didek A., Bates R., Blackwell S., Yim J., Ronneberger O., Bodenstein S., Zielinski M., Bridgland A., Potapenko A., Cowie A., Tunyasuvunakool K., Jain R., Clancy E., Kohli P., Jumper J., Hassabis D. (2021) Protein complex prediction with AlphaFold-Multimer. BioRxiv, 10.04.463034.","DOI":"10.1101\/2021.10.04.463034"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Fu C.H., Sakamoto K.M. (2007) PEG-asparaginase. Expert Opin. Pharmacother., 8, 1977-1984.","DOI":"10.1517\/14656566.8.12.1977"},{"key":"ref79","unstructured":"Postnov V.N., Naumysheva E.B., Korolev D.V., Galagudza M.M. (2013) Nanoscale carriers for drug delivery. Biotekhnosfera, 30, 16-29."},{"key":"ref80","unstructured":"Rizzari C., Citterio M., Zucchetti M., Conter V., Chiesa R., Colombini A., Malguzzi S., Silvestri D., d'Incalci M. (2006) A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica, 91, 24-31."},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Graham M.L. (2003) Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev., 55, 1293-1302.","DOI":"10.1016\/s0169-409x(03)00110-8"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Alpar H.O., Lewis D.A. (1985) Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. Biochem. Pharmacol., 34, 257-261.","DOI":"10.1016\/0006-2952(85)90133-9"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"He H., Ye J., Wang Y., Liu Q., Chung H.S., Kwon Y.M., Shin M.C., Lee K., Yang V.C. (2014) Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J. Control. Release., 176, 123-132.","DOI":"10.1016\/j.jconrel.2013.12.019"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Lorentz K.M., Kontos S., Diaceri G., Henry H., Hubbell J.A. (2015) Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase. Sci. Adv., 1, e1500112.","DOI":"10.1126\/sciadv.1500112"}],"container-title":["Biomeditsinskaya Khimiya"],"original-title":[],"language":"ru","deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T10:31:37Z","timestamp":1651228297000},"score":1,"resource":{"primary":{"URL":"http:\/\/pbmc.ibmc.msk.ru\/en\/article-en\/PBMC-2022-68-2-104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":84,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022]]},"published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.18097\/pbmc20226802104","relation":{},"ISSN":["2310-6905","2310-6972"],"issn-type":[{"value":"2310-6905","type":"electronic"},{"value":"2310-6972","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}